Opinion|Videos|July 3, 2024
Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration
Economic impacts on patients receiving treatment for PNH and a conversation surrounding treatment adherence are discussed by key opinion leaders.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In addition to mechanism of action, what role does route of administration play in terms of treatment selection? Please discuss your considerations for different modes of administration in terms of patient adherence and cost.
- What factors guide your decision-making process when initiating treatment for newly diagnosed patients versus adjusting or modifications for those already receiving complement inhibitor therapy?
- What factors prompt you to initiate discussions with patients about switching treatments?
Advertisement
Related to this article
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
4
Disease Extent Linked to Complications After Deep Endometriosis Surgery
5